Ulcerative colitis - treatment with biologicals

Teixeira, Fábio Vieira; Vilela, Eduardo García; Damião, Adérson Omar Mourão Cintra; Vieira, Andréa; Albuquerque, Idblan Carvalho de; Parente, José Miguel Luz; Chebli, Júlio Maria Fonseca; Ambrogini, Orlando; Hossne, Rogério Saad; Miszputen, Sender Jankiel

doi:10.1590/1806-9282.65.4.547

Cited by 6 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[38] Despite recent advances in IBD therapeutic, a high proportion of patients remain refractory to conventional treatment (e.g., sulfasalazine, aminosalicylates, cortisols, and immunosuppressants), so treatment options for moderately to severely active UC remain limited. [39] Anti-TNF-α agents such as infliximab, adalimumab, and golimumab, as well as anti-integrin agents such as vedolizumab, are usually the primary therapy for moderate-to-severe UC, and current evidence supports infliximab or vedolizumab as first-line therapy for moderate-to-severe UC, [39,40] but anti-TNF therapy appears to increase the risk of VTE in inflammatory disease. Infliximab can induce antiphospholipid antibodies, which can cause coagulation abnormalities by damaging endothelial and PLT functions, and then increase the risk of VTE.…”

Section: Discussionmentioning

confidence: 99%

Ulcerative colitis and thrombocytosis: Case report and literature review

et al. 2023

View full text Add to dashboard Cite

Rationale: Ulcerative colitis (UC) is an autoimmune disease of unknown etiology, sometimes associated with anemia and thrombocytosis. Platelets (PLTs) play a role in amplifying inflammatory and immune responses in chronic inflammation. This study discusses the diagnosis and treatment of a case of UC combined with secondary thrombocytosis and reviews the relevant literature. We report an interaction between thrombocytosis and UC to raise clinicians' awareness of this condition.Patient concerns: In the current report, we discuss the case of a 30-year-old female patient who presented with frequent diarrhea and thrombocytosis.Diagnosis: Severe UC combined with intestinal infection was diagnosed based on colonoscopy and intestinal biopsy. The patient had a PLT count >450 × 10 9 /L and was diagnosed with reactive thrombocytosis. Interventions and outcomes:The patient was discharged from the hospital in remission after receiving vedolizumab and anticoagulant treatment.Lessons: In patients with severe UC with thrombocytosis, clinicians should pay attention to PLTs promoting inflammatory progression, as well as screening for venous thromboembolism risk and prophylactic anti-venous thromboembolism therapy at the time of dosing to avoid adverse effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Ulcerative colitis and thrombocytosis: Case report and literature review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In comparison to the placebo groups in both studies, baricitinib 4 mg significantly improved both EB and EL hair loss scores. [27][28][29] Another analysis of the BRAVE-AA1 and BRAVE-AA2 trails was performed to establish the effectiveness and safety of baricitinib for treating patients with an atopic background. [30][31][32] The safety profiles of the drug and the level of hair regrowth in individuals with AA were found to be unaffected by atopic background.…”

Section: Baricitinib (Olumiant) Fda Approvalmentioning

confidence: 99%

Review of efficacy of baricitinib in the treatment of alopecia areata

Alenazi

Altamimi²

2023

Int J Res Dermatol

View full text Add to dashboard Cite

Alopecia areata (AA) is a long-term autoimmune condition characterized by patchy, non-scarring hair loss. It involves an autoimmune inflammatory process that gives immunity privilege to some hair follicles, while subsequent inflammatory attacks target previously normal hair follicles. One of the most important discoveries in the pathogenesis of this disease is the Janus kinase (JAK)-signal transducer and activator of the transcription (STAT) pathway. Now that a greater understanding of the immunological processes contributing to the pathogenesis has been gained, current trials’ focus was on managing the immunological reaction involved in this disease. Baricitinib is a new first-generation JAK inhibitor that has been studied in multiple trials. This study's objectives were to review existing research and summarize information on the use of Baricitinib to treat AA. The Medline database was searched for relevant published research papers using variations of the following keywords: “AA,” “Baricitinib,” and “JAK inhibitors.” The search covered studies published from 2010–2022. Our findings showed that baricitinib’s use for severe AA in multiple studies generally led to improvement of patients’ conditions with minimal side effects.

show abstract

“…[ 5 6 7 ] Based on the mentioned problems and growing incidence rate of UC, it is necessary to try natural and traditional products to find better medications. [ 8 ] Vitis vinifera (grape, black royal cultivar, Vitaceae) is one of the oldest fruits indigenous to Asia, Europe, and North America. This plant, botanically a berry, grows in a climbing inosculated pattern.…”

Section: Introductionmentioning

confidence: 99%